# Tyra Biosciences, Inc.: financial statements, quarterly

TYRA · Nasdaq · CIK 1863127 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tyra.md) · [Financials](/companies/tyra/financials.md) · [Filings](/companies/tyra/filings.md) · [Insiders](/companies/tyra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tyra/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [19.3](/filings/0000950170-24-123346.md) | [20.7 d](/filings/0000950170-25-046124.md) | [17.2](/filings/0000950170-25-066942.md) | [18.0](/filings/0000950170-25-108899.md) | [22.7](/filings/0001193125-25-266967.md) | [22.2 d](/filings/0001193125-26-085490.md) | [25.0](/filings/0001193125-26-220645.md) | [24.3](/filings/0001193125-26-332995.md) | [25.5](/filings/0001193125-25-266967.md) | [28.2 d](/filings/0001193125-26-085490.md) | [33.5](/filings/0001193125-26-220645.md) | [39.2](/filings/0001193125-26-332995.md) |
| Selling, general and administrative | $m | [0.0](/filings/0000950170-23-060276.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(24.0)](/filings/0000950170-24-123346.md) | [(25.6) d](/filings/0000950170-25-046124.md) | [(22.3)](/filings/0000950170-25-066942.md) | [(23.5)](/filings/0000950170-25-108899.md) | [(28.6)](/filings/0001193125-25-266967.md) | [(29.7) d](/filings/0001193125-26-085490.md) | [(31.9)](/filings/0001193125-26-220645.md) | [(31.5)](/filings/0001193125-26-332995.md) | [(32.9)](/filings/0001193125-25-266967.md) | [(36.5) d](/filings/0001193125-26-085490.md) | [(42.0)](/filings/0001193125-26-220645.md) | [(49.0)](/filings/0001193125-26-332995.md) |
| Net income | $m | [(21.2)](/filings/0000950170-24-123346.md) | [(22.8) d](/filings/0000950170-25-046124.md) | [(18.2)](/filings/0001193125-25-266967.md) | [(18.7)](/filings/0001193125-25-266967.md) | [(24.0)](/filings/0001193125-25-266967.md) | [(25.6) d](/filings/0001193125-26-085490.md) | [(28.1)](/filings/0001193125-26-332995.md) | [(28.1)](/filings/0001193125-26-332995.md) | [(29.9)](/filings/0001193125-25-266967.md) | [(33.8) d](/filings/0001193125-26-085490.md) | [(39.3)](/filings/0001193125-26-332995.md) | [(45.6)](/filings/0001193125-26-332995.md) |
| Diluted EPS | $ per share | [(0.49)](/filings/0000950170-24-123346.md) | not reported | [(0.35)](/filings/0000950170-25-066942.md) | [(0.32)](/filings/0000950170-25-108899.md) | [(0.41)](/filings/0001193125-25-266967.md) | not reported | [(0.47)](/filings/0001193125-26-220645.md) | [(0.47)](/filings/0001193125-26-332995.md) | [(0.50)](/filings/0001193125-25-266967.md) | not reported | [(0.64)](/filings/0001193125-26-220645.md) | [(0.69)](/filings/0001193125-26-332995.md) |
| Basic EPS | $ per share | [(0.49)](/filings/0000950170-24-123346.md) | not reported | [(0.35)](/filings/0000950170-25-066942.md) | [(0.32)](/filings/0000950170-25-108899.md) | [(0.41)](/filings/0001193125-25-266967.md) | not reported | [(0.47)](/filings/0001193125-26-220645.md) | [(0.47)](/filings/0001193125-26-332995.md) | [(0.50)](/filings/0001193125-25-266967.md) | not reported | [(0.64)](/filings/0001193125-26-220645.md) | [(0.69)](/filings/0001193125-26-332995.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [216](/filings/0000950170-24-123346.md) | [58.0](/filings/0000950170-25-046124.md) | [254](/filings/0000950170-25-066942.md) | [99.5](/filings/0000950170-25-108899.md) | [104](/filings/0001193125-25-266967.md) | [92.0](/filings/0001193125-26-085490.md) | [101](/filings/0001193125-26-220645.md) | [98.5](/filings/0001193125-26-332995.md) | [62.0](/filings/0001193125-25-266967.md) | [77.4](/filings/0001193125-26-332995.md) | [85.0](/filings/0001193125-26-220645.md) | [73.8](/filings/0001193125-26-332995.md) |
| Current assets | $m | [225](/filings/0000950170-23-060276.md) | [212](/filings/0000950170-25-046124.md) | [391](/filings/0000950170-24-056971.md) | [379](/filings/0000950170-24-092778.md) | [366](/filings/0000950170-24-123346.md) | [347](/filings/0001193125-26-085490.md) | [325](/filings/0000950170-25-066942.md) | [302](/filings/0000950170-25-108899.md) | [281](/filings/0001193125-25-266967.md) | [265](/filings/0001193125-26-332995.md) | [395](/filings/0001193125-26-220645.md) | [367](/filings/0001193125-26-332995.md) |
| Total assets | $m | [238](/filings/0000950170-23-060276.md) | [226](/filings/0000950170-25-046124.md) | [405](/filings/0000950170-24-056971.md) | [392](/filings/0000950170-24-092778.md) | [381](/filings/0000950170-24-123346.md) | [364](/filings/0001193125-26-085490.md) | [343](/filings/0000950170-25-066942.md) | [321](/filings/0000950170-25-108899.md) | [302](/filings/0001193125-25-266967.md) | [283](/filings/0001193125-26-332995.md) | [412](/filings/0001193125-26-220645.md) | [383](/filings/0001193125-26-332995.md) |
| Current liabilities | $m | [10.1](/filings/0000950170-23-060276.md) | [15.3](/filings/0000950170-25-046124.md) | [8.7](/filings/0000950170-24-056971.md) | [10.4](/filings/0000950170-24-092778.md) | [12.4](/filings/0000950170-24-123346.md) | [14.6](/filings/0001193125-26-085490.md) | [14.2](/filings/0000950170-25-066942.md) | [13.8](/filings/0000950170-25-108899.md) | [15.9](/filings/0001193125-25-266967.md) | [18.1](/filings/0001193125-26-332995.md) | [19.3](/filings/0001193125-26-220645.md) | [24.6](/filings/0001193125-26-332995.md) |
| Total liabilities | $m | [16.2](/filings/0000950170-23-060276.md) | [21.6](/filings/0000950170-25-046124.md) | [14.9](/filings/0000950170-24-056971.md) | [16.4](/filings/0000950170-24-092778.md) | [18.3](/filings/0000950170-24-123346.md) | [20.4](/filings/0001193125-26-085490.md) | [19.9](/filings/0000950170-25-066942.md) | [19.4](/filings/0000950170-25-108899.md) | [21.3](/filings/0001193125-25-266967.md) | [23.4](/filings/0001193125-26-332995.md) | [24.5](/filings/0001193125-26-220645.md) | [29.7](/filings/0001193125-26-332995.md) |
| Shareholders' equity | $m | [222](/filings/0000950170-24-123346.md) | [204](/filings/0001193125-26-085490.md) | [390](/filings/0001193125-25-266967.md) | [376](/filings/0001193125-25-266967.md) | [362](/filings/0001193125-25-266967.md) | [343](/filings/0001193125-26-332995.md) | [324](/filings/0001193125-26-332995.md) | [302](/filings/0001193125-26-332995.md) | [281](/filings/0001193125-25-266967.md) | [259](/filings/0001193125-26-332995.md) | [388](/filings/0001193125-26-332995.md) | [354](/filings/0001193125-26-332995.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.1) d](/filings/0000950170-24-123346.md) | [(13.5) d](/filings/0000950170-25-046124.md) | [(22.0)](/filings/0000950170-25-066942.md) | [(10.3) d](/filings/0000950170-25-108899.md) | [(17.9) d](/filings/0001193125-25-266967.md) | [(19.6) d](/filings/0001193125-26-085490.md) | [(25.5)](/filings/0001193125-26-220645.md) | [(23.7) d](/filings/0001193125-26-332995.md) | [(22.4) d](/filings/0001193125-25-266967.md) | [(23.6) d](/filings/0001193125-26-085490.md) | [(32.6)](/filings/0001193125-26-220645.md) | [(31.1) d](/filings/0001193125-26-332995.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-123346.md) | [0.6 d](/filings/0000950170-25-046124.md) | [0.1](/filings/0000950170-25-066942.md) | [0.5 d](/filings/0000950170-25-108899.md) | [0.1 d](/filings/0001193125-25-266967.md) | [0.0 d](/filings/0001193125-26-085490.md) | [0.0](/filings/0001193125-26-220645.md) | [0.0 d](/filings/0001193125-26-332995.md) | [0.0 d](/filings/0001193125-25-266967.md) | [0.1 d](/filings/0001193125-26-085490.md) | [0.1](/filings/0001193125-26-220645.md) | [0.1 d](/filings/0001193125-26-332995.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.0](/filings/0000950170-23-060276.md) | [42.4](/filings/0000950170-24-056971.md) | [42.6](/filings/0000950170-24-092778.md) | [42.9](/filings/0000950170-24-123346.md) | [52.2](/filings/0000950170-25-066942.md) | [58.7](/filings/0000950170-25-108899.md) | [58.9](/filings/0001193125-25-266967.md) | [59.3](/filings/0001193125-26-220645.md) | [59.6](/filings/0001193125-26-332995.md) | [59.7](/filings/0001193125-25-266967.md) | [61.7](/filings/0001193125-26-220645.md) | [66.0](/filings/0001193125-26-332995.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 59,676,939 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332995.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.